Dr. George D. Demetri on Trabectedin or Dacarbazine Treatments for Patients With Advanced Leiomyosarcoma or Liposarcoma
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.
In this preplanned analysis, researchers were trying to limit any excess heterogeneity in order to get a clear answer as to whether trabectedin is more active than dacarbazine. There is no question, Demetri says, that there was a progression-free survival (PFS) difference but no overall survival (OS) difference.
Demetri says the lack of OS difference was due to post-study therapies virtually all patients went on to receive other agents after this protocol. It's worth noting, he says, that the trial was designed in 2010 and pazopanib (Votrient) was approved in 2012.
First-in-Class Drug AMG 193 Exploits Tumor Weakness for Targeted Therapy
September 17th 2024In a first-in-human trial, AMG 193, a drug targeting a specific mutation in tumors, showed promising results in reducing tumor size and spread in various cancers, with an acceptable safety profile.
Read More
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
